Trial Profile
A phase II single arm clinical trial of a Tailored ImmunoTherapy Approach with Nivolumab in subjects with metastatic or advanced Transitional Cell Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Bladder cancer; Carcinoma; Renal cancer; Squamous cell cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
- Focus Therapeutic Use
- Acronyms TITAN TCC
- 24 Oct 2023 Results of final data of using a tailored approach with N and N+I boosts for non-response, presented at the 48th European Society for Medical Oncology Congress
- 11 Jul 2023 This trial has been completed in Germany (End Date: 17 Feb 2023), according to European Clinical Trials Database record.
- 10 May 2023 This trial has been completed in Austria (End Date: 17 Feb 2023), according to European Clinical Trials Database record.